A specific phosphoinositide 3-kinase (PI3K) inhibitor, wortmannin, was used to test the effect of PI3K inhibition on the secretion of CCL-2 in gastric cancer.
IFN-γ and IL-10 levels were significantly higher in early (I/II) and late stage (III/IV) gastric cancer; IL-1β and IL-8 were higher and MCP-1 was lower only in late stage (IV) patients.
Our study provides the first evidence that the NFKB1 rs230510 and CCL2rs4586 are significantly associated with the clinical outcome in patients with locoregional gastric cancer.
Our data suggest that the genetic polymorphism CCL2A-2518G may not only be associated with an increased risk of gastric cancer, but also with advanced stage of gastric cancer in the Chinese population.